MERIT MEDICAL SYSTEMS INC — fact timeline

MERIT MEDICAL SYSTEMS INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-13 meeting.

“Proposal 5 - Ratification of Appointment of Independent Registered Public Accounting Firm The voting results with respect to the proposal to ratify the appointment of Deloitte & Touche LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 were as follows: ​ ​ ​ For Against Abstain 50,369,058 2,151,392 11,623”

MERIT MEDICAL SYSTEMS INC shareholders approved Approval of the Merit Medical Systems, Inc. 2026 Employee Stock Purchase Plan at the 2026-05-13 meeting.

“Proposal 4 – Approval of the Merit Medical Systems, Inc. 2026 Employee Stock Purchase Plan The voting results with respect to the proposal to approve the Merit Medical Systems, Inc. 2026 Employee Stock Purchase Plan were as follows: For Against Abstain Broker Non-Votes 50,109,861 151,208 7,740 2,263,264”

MERIT MEDICAL SYSTEMS INC shareholders approved Approval of the Merit Medical Systems, Inc. 2026 Equity Incentive Plan at the 2026-05-13 meeting.

“Proposal 3 - Approval of the Merit Medical Systems, Inc. 2026 Equity Incentive Plan The voting results with respect to the proposal to approve the Merit Medical Systems, Inc. 2026 Equity Incentive Plan were as follows: For Against Abstain Broker Non-Votes 48,750,003 1,510,844 7,962 2,263,264”

MERIT MEDICAL SYSTEMS INC shareholders approved Non-binding advisory proposal to approve the compensation of the Company’s named executive officers, otherwise known as a “say-on-pay” vote at the 2026-05-13 meeting.

“Proposal 2 - Advisory Vote on Executive Compensation The voting results with respect to a non-binding advisory proposal to approve the compensation of the Company’s named executive officers were as follows: For Against Abstain Broker Non-Votes 48,835,995 1,415,355 17,459 2,263,264”

MERIT MEDICAL SYSTEMS INC shareholders approved Election of four nominees, three to serve as directors until the Company’s 2029 Annual Meeting of Shareholders and one to serve as a director until the Company’s 2027 Annual Meeting of Shareholders, or until each of his or her successors is duly elected and qualified at the 2026-05-13 meeting.

“Proposal 1 - Election of Directors The votes cast for or withheld for each director nominee for the term length indicated were as follows: Director Nominee For Against Abstain Broker Non-Votes Martha G. Aronson (three year term) 50,057,322 197,560 13,927 2,263,264 Lonny J. Carpenter (three year term) 49,048,111 1,206,492 14,206 2,263,264 Lynne N. Ward (one year term) 49,027,930 1,115,001 125,878 2,263,264 Scott R. Ward (three year term) ​ 50,071,431 ​ 176,296 ​ 21,082 ​ 2,263,264”

MERIT MEDICAL SYSTEMS INC: Board adopted Fifth Amended and Restated Bylaws, making various clarifications and updates (effective 2026-05-14).

“On May 14, 2026, the Board approved and adopted the Fifth Amended and Restated Bylaws of the Company (the “Fifth A&R Bylaws”).”

MERIT MEDICAL SYSTEMS INC reported the quarter ended March 31, 2026 results: revenue $381.9 million, EPS GAAP EPS $0.68.

“​ ​ ​ ​ ​ ​ FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS FIRST QUARTER 2026 RESULTS AND UPDATES FULL-YEAR GUIDANCE ​ Financial Highlights† ● Reported revenue of $381.9 million, up 7% ● Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively o Constant currency revenue, organic* increased 4%, excluding revenue”

Fred P. Lampropoulos resigned as President at MERIT MEDICAL SYSTEMS INC.

“In connection with Mr. Wright’s appointment, Fred P. Lampropoulos resigned as President of Merit. Mr. Lampropoulos will continue to serve as Merit’s Chief Executive Officer.”

Joseph C. Wright was appointed as President at MERIT MEDICAL SYSTEMS INC.

“The Board of Directors of Merit Medical Systems, Inc. (“Merit”) appointed Joseph C. Wright as President of Merit, effective as of May 15, 2024.”

MERIT MEDICAL SYSTEMS INC reported first quarter ended March 31, 2024 results: revenue $323.5 million, EPS $0.48.

“mike.piccinino@westwicke.com ​ ​ ​ ​ ​ ​ ​ ​ FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2024 ● Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023 ● Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023 ● Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023 ● Q1 2024”

MERIT MEDICAL SYSTEMS INC reported Q4 2023 results: EPS 0.47.

“Q4 2023 reported revenue of $324.5 million, up 10.6% year-over-year”

MERIT MEDICAL SYSTEMS INC reported year ended December 31, 2023 results: revenue $1.255 billion - $1.259 billion.

“FOURTH QUARTER AND YEAR END 2023 RESULTS AND ISSUE FISCAL YEAR 2024 GUIDANCE ON FEBRUARY 28, 2024 ​ ● 2023 reported preliminary unaudited revenue in the range of approximately $1.255 billion - $1.259 billion, up approximately 9.0% - 9.4% year-over-year ● 2023 preliminary unaudited constant currency revenue* in the range of up approximately 9.6% - 9.9% year over year”

MERIT MEDICAL SYSTEMS INC incurred convertible notes of $747.5 million with U.S. Bank Trust Company, National Association at 3.00% maturing February 1, 2029.

“On December 8, 2023, Merit Medical Systems, Inc. (“Merit”) closed an offering of $747.5 million aggregate principal amount of its 3.00% Convertible Senior Notes due 2029”

MERIT MEDICAL SYSTEMS INC entered into Base Capped Call Transactions with certain of the initial purchasers and/or their respective affiliates and certain other financial institutions (effective 2023-12-05).

“On December 5, 2023, in connection with the pricing of the Notes, Merit entered into privately negotiated capped call transactions (the “Base Capped Call Transactions”) with certain of the initial purchasers and/or their respective affiliates and certain other financial institutions (the “Option Counterparties”).”

MERIT MEDICAL SYSTEMS INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $747.5 million aggregate principal amount (effective 2023-12-08).

“On December 8, 2023, Merit Medical Systems, Inc. (“Merit”) closed an offering of $747.5 million aggregate principal amount of its 3.00% Convertible Senior Notes due 2029 (the “Notes”).”

MERIT MEDICAL SYSTEMS INC reported for the quarter ended September 30, 2023 results: revenue $315.2 million, EPS $0.44. Guidance raised.

“mike.piccinino@westwicke.com ​ ​ ​ ​ ​ ​ ​ ​ FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2023 ​ ● Q3 2023 reported revenue of $315.2 million, up 9.8% year-over-year ● Q3 2023 constant currency revenue* up 9.7% year over year ● Q3 2023 constant currency revenue, organic* up 7.1% year-over-year ● Q3 2023 GAAP operating”

MERIT MEDICAL SYSTEMS INC reported Q2 2023 results: revenue $320.1 million, EPS $0.35.

“MERIT MEDICAL REPORTS RESULTS FOR SECOND QUARTER JUNE 30, 2023 ​ ● Q2 2023 reported revenue of $320.1 million, up 8.5% year-over-year ● Q2 2023 constant currency revenue* up 9.4% year over year ● Q2 2023 constant currency revenue, organic* up 9.1% year-over-year ● Q2 2023 GAAP operating margin of 9.0%, compared to 7.9% in Q2 2022 ● Q2 2023 non-GAAP operating margin* of 19.9%, compared to 19.1% in Q2 2022 ● Q2 2023 GAAP EPS $0.35, compared to $0.27 in Q2 2022 ● Q2 2023 non-GAAP EPS* of $0.81, compared to $0.73 in Q2 2022”

MERIT MEDICAL SYSTEMS INC incurred credit facility of $150,000,000 term loan and $700,000,000 revolving credit facility with Wells Fargo Bank, National Association (Agent), Bank of America, N.A., HSBC Bank USA, National Association, U.S. Bank National Association, Truist Bank, TD Bank, Huntington Bank, Regions Bank at Base Rate plus Applicable Margin; Adjusted Term SOFR plus Applicable Margin; Adj maturing June 6, 2028.

“to the Fourth Amended Credit Agreement as Lenders. Pursuant to the terms of the Fourth Amended Credit Agreement, the Lenders have agreed to make a term loan in the amount of $150,000,000 and revolving credit loans up to an aggregate amount of up to $700,000,000, inclusive of sub-facilities of up to $40,000,000 for multicurrency borrowings, up to $40,000,000 for”

MERIT MEDICAL SYSTEMS INC entered into Fourth Amended Credit Agreement with Wells Fargo Bank, National Association, Bank of America, N.A., HSBC Bank USA, National Association, U.S. Bank National Association, Truist Bank, TD Bank, Huntington Bank and Regions Bank valued at $150,000,000 term loan and revolving credit loans up to $700,000,000 (effective 2023-06-06).

“Merit entered into the Fourth Amended and Restated Credit Agreement on June 6, 2023 (the “Fourth Amended Credit Agreement”) with certain lenders identified therein”

MERIT MEDICAL SYSTEMS INC updated its full-year 2023 guidance (reaffirmed).

“Merit re-affirms full-year 2023 financial guidance on stand-alone basis and updates full-year 2023 financial guidance to include partial-year impact from acquisitions”

MERIT MEDICAL SYSTEMS INC entered into Purchase Agreement with AngioDynamics, Inc. valued at $100 million (effective 2023-06-08).

“On June 8, 2023, Merit entered into an Asset Purchase Agreement (the “Purchase Agreement”) with AngioDynamics, Inc., a Delaware corporation (“AngioDynamics”), pursuant to which Merit acquired a portfolio of dialysis catheter products, including various assets related thereto, and the BioSentry ® Biopsy Tract Sealant System from AngioDynamics (collectively, the “Acquisition”).”

MERIT MEDICAL SYSTEMS INC shareholders approved a proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-18 meeting.

“The voting results with respect to the proposal to ratify the appointment of Deloitte & Touche LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 were as follows: ​ For Against Abstain 50,876,135 ​ 2,211,426 ​ 37,005 ​ Accordingly, the Company’s shareholders ratified the appointment of Deloitte and Touche LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”

MERIT MEDICAL SYSTEMS INC shareholders approved a non-binding advisory proposal to approve the frequency of votes on executive compensation of the Company’s named executive officers at the 2023-05-18 meeting.

“The results of the voting on a non-binding advisory proposal to approve the frequency of votes on compensation of the Company’s named executive officers were as follows: ​ 1 Year 2 Years 3 Years Abstain 49,802,382 ​ 30,676 ​ 2,069,476 ​ 17,601 ​ ​ Accordingly, a majority of votes cast with respect to the frequency of votes on compensation proposal were “for” 1 year, as disclosed in the Proxy Statement.”

MERIT MEDICAL SYSTEMS INC shareholders approved a non-binding advisory proposal to approve the compensation of the Company’s named executive officers, otherwise known as a “say-on-pay” vote at the 2023-05-18 meeting.

“The results of the voting on a non-binding advisory proposal to approve the compensation of the Company’s named executive officers were as follows: ​ For Against Abstain Broker Non-Votes 49,890,989 ​ 1,994,786 ​ 34,360 ​ 1,204,431 ​ Accordingly, a majority of votes cast with respect to the advisory “say-on-pay” proposal were “for” approval of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.”

MERIT MEDICAL SYSTEMS INC shareholders approved the election of three nominees, each to serve as a director of the Company until the 2026 Annual Meeting of Shareholders and until his or her successor is duly elected and qualified at the 2023-05-18 meeting.

“The votes cast for or withheld for each director nominee were as follows: ​ Director Nominee For Against ​ Abstain ​ Broker Non-Votes Lonny J. Carpenter 50,024,416 ​ 1,862,957 ​ 32,762 ​ 1,204,431 David K. Floyd 49,834,579 ​ 2,052,794 ​ 32,762 ​ 1,204,431 Lynne N. Ward 49,228,089 ​ 2,657,197 ​ 34,849 ​ 1,204,431 ​ Accordingly, each of the three nominees listed above was elected to serve as a director of the Company until the 2026 Annual Meeting of Shareholders and until his or her successor is duly elected and qualified.”

MERIT MEDICAL SYSTEMS INC reported financial results for quarter ended March 31, 2023.

“On April 26, 2023, the Company issued a press release announcing its operating and financial results for the quarter ended March 31, 2023.”

MERIT MEDICAL SYSTEMS INC updated its the year ended December 31, 2022 guidance (initiated).

“On February 22, 2023, the Company issued a press release announcing its operating and financial results for the quarter and year ended December 31, 2022.”

MERIT MEDICAL SYSTEMS INC reported the fourth quarter ended December 31, 2022 results: revenue $293.4 million, EPS $0.58. Guidance initiated.

“● Q4 2022 reported revenue of $293.4 million, up 5.4% compared to Q4 2021 ● Q4 2022 constant currency revenue, organic* up 8.2% compared to Q4 2021 ● Q4 2022 GAAP operating margin of 10.4%, compared to 7.9% in Q4 2021 ● Q4 2022 non-GAAP operating margin* of 17.8%, compared to 17.4% in Q4 2021 ● Q4 2022 GAAP EPS $0.58, compared to $0.36 in Q4 2021”

MERIT MEDICAL SYSTEMS INC updated its fiscal year 2023 guidance (initiated).

“MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022 ISSUES FISCAL YEAR 2023 GUIDANCE”

MERIT MEDICAL SYSTEMS INC reported financial results for the year ended December 31, 2022.

“On February 22, 2023, Merit Medical Systems, Inc. (the “Company”) issued a press release announcing its operating and financial results for the quarter and year ended December 31, 2022.”

MERIT MEDICAL SYSTEMS INC reported Q4 2022 results: revenue $293.4 million, EPS GAAP EPS $0.58.

“● Q4 2022 reported revenue of $293.4 million, up 5.4% compared to Q4 2021 ● Q4 2022 constant currency revenue, organic* up 8.2% compared to Q4 2021 ● Q4 2022 GAAP operating margin of 10.4%, compared to 7.9% in Q4 2021 ● Q4 2022 non-GAAP operating margin* of 17.8%, compared to 17.4% in Q4 2021 ● Q4 2022 GAAP EPS $0.58, compared to $0.36 in Q4 2021 ● Q4 2022 non-GAAP EPS* of $0.79, compared to $0.71 in Q4 2021”

Ronald A. Frost departed as Chief Operating Officer at MERIT MEDICAL SYSTEMS INC.

“On August 26, 2022, the Company and Ronald A. Frost entered into a Separation Agreement setting forth the terms and conditions of his separation from the Company”

Neil Peterson was appointed as Chief Operating Officer at MERIT MEDICAL SYSTEMS INC.

“Neil Peterson, age 56, was appointed as the Company’s Chief Operating Officer.”

Ron Frost retired as Chief Operating Officer at MERIT MEDICAL SYSTEMS INC.

“Ron Frost has retired from his position as the Company’s Chief Operating Officer, effective April 19, 2022.”

Justin Lampropoulos was terminated as President, Europe, Middle East and Africa at MERIT MEDICAL SYSTEMS INC.

“Effective as of October 19, 2021, Merit Medical Systems, Inc., through a wholly-owned subsidiary, terminated the employment of Justin Lampropoulos, President, Europe, Middle East and Africa.”